When evaluating a single 75-mg encorafenib capsule in the TIM-1system, trends in maximum and total bioaccessibility were similarto those seen with AUC and Cmax acrossthe range of different clinical administration conditions studied.This dose differs from that used in the 2 clinical studies; however,encorafenib is approximately dose proportional in the dose range of50 to 700 mg QD after a single dose,33 allowingfor the results to be applied to the clinically approved doses forboth BRAF mutant melanoma (450 mg orally QD) and BRAF mutant mCRC(300 mg orally QD). Here, BRAF is linked to melanoma.